omeprazole has been researched along with Kidney Tubular Transport, Inborn Error in 4 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, a randomized controlled trial that compared clopidogrel alone with the combination of clopidogrel and omeprazole found no increase in adverse cardiovascular outcomes and a reduction in the rate of adverse gastrointestinal outcomes attributable to omeprazole." | 2.48 | Recent safety concerns with proton pump inhibitors. ( Chen, J; Howden, CW; Leontiadis, GI; Yuan, YC, 2012) |
| "Omeprazole-treated rats had significantly decreased the width of tight junction, villous length, and absorptive area of duodenum, jejunum, and ileum compared to control rats." | 1.62 | Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats. ( Chamniansawat, S; Kampuang, N; Suksridechacin, N; Thongon, N, 2021) |
| " In this study, the reports submitted to the Adverse Event Reporting System (AERS) of the US Food and Drug Administration (FDA) were evaluated to assess omeprazole and esomeprazole in terms of susceptibility to hypomagnesaemia." | 1.38 | Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chamniansawat, S | 1 |
| Kampuang, N | 1 |
| Suksridechacin, N | 1 |
| Thongon, N | 1 |
| Chen, J | 1 |
| Yuan, YC | 1 |
| Leontiadis, GI | 1 |
| Howden, CW | 1 |
| Rodríguez Ortega, P | 1 |
| Rebollo Pérez, I | 1 |
| Laínez López, M | 1 |
| Roldán Mayorga, E | 1 |
| Hernández Lavado, R | 1 |
| Creagh Cerquera, R | 1 |
| Tamura, T | 1 |
| Sakaeda, T | 1 |
| Kadoyama, K | 1 |
| Okuno, Y | 1 |
1 review available for omeprazole and Kidney Tubular Transport, Inborn Error
| Article | Year |
|---|---|
Recent safety concerns with proton pump inhibitors.
Topics: Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fractures, Spontaneous; Gastrointestinal | 2012 |
3 other studies available for omeprazole and Kidney Tubular Transport, Inborn Error
| Article | Year |
|---|---|
Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats.
Topics: Animals; Atrophy; Gastric Acid; Hypercalciuria; Inflammation; Intestinal Mucosa; Lymphocyte Activati | 2021 |
Severe hypomagnesemia and hypoparathyroidism induced by omeprazole.
Topics: Humans; Hypercalciuria; Hypoparathyroidism; Male; Middle Aged; Nephrocalcinosis; Omeprazole; Proton | 2013 |
Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Data Mining; Enzyme Inhibitors; Esomeprazole; Humans; Hyper | 2012 |